
==== Front
ACS OmegaACS OmegaaoacsodfACS Omega2470-1343American Chemical Society 3055598210.1021/acsomega.8b02090ArticleCisplatin-Loaded Graphene Oxide/Chitosan/Hydroxyapatite
Composite as a Promising Tool for Osteosarcoma-Affected Bone Regeneration Sumathra Murugan †Sadasivuni Kishor Kumar ‡Kumar S. Suresh §Rajan Mariappan *†† Biomaterials
in Medicinal Chemistry Laboratory, Department of Natural Products
Chemistry, School of Chemistry, Madurai
Kamaraj University, Madurai625021, India‡ Centre
for Advanced Materials, Qatar University, P.O. Box 2713, Doha, Qatar§ Department
of Medical Microbiology and Parasitology, Universiti Putra Malaysia, Serdang 43400, Malaysia* E-mail: rajanm153@gmail.com. Tel: +91 9488014084.01 11 2018 30 11 2018 3 11 14620 14633 18 08 2018 22 10 2018 Copyright © 2018 American Chemical
Society2018American Chemical
SocietyThis is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.

Presently, tissue engineering approaches
have been focused toward
finding new potential scaffolds with osteoconductivity on bone-disease-affected
cells. This work focused on the cisplatin (CDDP)-loaded graphene oxide
(GO)/hydroxyapatite (HAP)/chitosan (CS) composite for enhancing the
growth of osteoblast cells and prevent the development of osteosarcoma
cells. The prepared composites were characterized for the confirmation
of composite formation using Fourier transform infrared spectroscopy,
scanning electron microscopy, transmission electron microscopy, and
X-ray diffraction techniques. A flowerlike morphology was observed
for the GO/HAP/CS-3/CDDP composite. UV–vis spectroscopy was
used to observe the controlled release of CDDP from the GO/HAP/CS-3/CDDP
composite, and 67.34% of CDDP was released from the composite over
a time period of 10 days. The GO/HAP/CS-3/CDDP nanocomposites showed
higher viability in comparison with GO/HAP/CS-3 on MG63 osteoblast-like
cells and higher cytotoxicity against cancer cells (A549). The synthesized
composite was found to show enhanced proliferative, adhesive, and
osteoinductive effects on the alkaline phosphatase activity of osteoblast-like
cells. Our results suggested that the CDDP-loaded GO/HAP/CS-3 nanocomposite
has an immense prospective as a bone tissue replacement in the bone-cancer-affected
tissues.

document-id-old-9ao8b02090document-id-new-14ao-2018-02090bccc-price
==== Body
1 Introduction
Phosphates
of calcium are of immense impact due to their astonishing
biocompatibility and bioactivity making them useful in biomedicine
fields analogous to orthopedics, drug delivery, and dentistry. Among
the calcium phosphate compounds, hydroxyapatite (HAP) is the most
valuable one because of its potential use in bone tissue engineering
and also because it exhibits excellent osteoinductivity.1 The relevance of HAP in load-bearing implants
is constrained because of the typical fragility with small fracture
toughness.2 Generally, HAP can be combined
with different varieties of natural polymers, synthetic polymers,
and graphene family materials.3

The
graphene family nanomaterials include several graphene derivatives,
such as few-layered graphene, graphene oxide (GO), reduced graphene
oxide, ultrathin graphite, and graphene nanosheets that were used
in various biomedical applications.3 These
all differ from each other in terms of surface properties, number
of layers, and size. GO enhances or alters the required properties
for a specific application. Nanosheets of GO is an attractive nanomaterial,
which have two-dimensional property, mechanical potency, biocompatibility,
quickly accumulated curiosity in the biomedical and pharmaceutical
fields,4 potential release vehicles for
drugs, biological macromolecules cellular coloring agents and implantable
tissues.5,6 Current studies signify that the inclusion
of GO could substantially provide mechanical strength to GO-related
composites7,8 and also that GO might endorse the adhesion
of osteoblasts and propagation of osteoblast activity.9,10 The concern of promoting apatite nucleation strength opens up a
further advantage of GO in HAP-based composite preparation.11

Recently, chitosan (CS) has found diversity
of applications such
as in drug delivery, food packaging, forming a membrane for separation,
environmental applications, and tissue engineering for admissible
improvement of the bone graft materials.12 CS possesses a lot of superior biomedical properties such as anti-inflammatory
and antimicrobial properties, biocompatibility, biodegradability,
nonantigenicity, osteoconductivity, and nontoxicity.13,14 Moreover, for the CS molecule to be used as a structural sustainer
in tissue regeneration, it should have sufficient surface area to
accommodate live cells effectively; the CS structure allows appropriate
transport of nutrients for cell growth. Its chemical structure possesses
the ability to regenerate primary tissue cells.15,16 In tissue engineering, CS and HAP composites have the ability to
promote a great proliferative activity in osteoblasts.17 A vastly permeable, three-dimensional structure
is significant for tissue engineering materials for replicating the
extracellular matrix (ECM) to set a proper microenvironment for cell
attachment and propagation.18,19 Among these materials,
GO, HAP, and CS are generally chosen because of the effectual functional
features such as their bone-resembling properties, which can successfully
encourage osteoblast enlargement, stimulate mineralization of osteoid,
and suppress the osteosarcoma (OS) cells.20

In this study, we evaluate the impact of anticancer drug cisplatin
(CDDP) loaded on CS-functionalized HAP on a GO platform composite
on bone formation during bone repair in osteosarcoma (OS).21,22 OS is a greatly malignant mesenchymal cancer of bone in which the
malignant cells create osteoid. Among all available chemotherapeutic
agents, anthracycline and platinum-based drugs are used most commonly,
and particularly CDDP is solitary of the mainly effectual anticancer
agents for reducing the feasible cell quantity.23 This action could lead to the CDDP-induced cell death along
with cell propagation reticence.

2 Results
and Discussion
2.1 Fourier Transform Infrared
(FTIR) Analysis
Figure 1A,a shows
the absorption bands at 473, 565, 602, 963, 1035, and 1098 cm–1, which are the distinguishing peaks of a PO43– group. The small peak at 473 cm–1 is ascribed to the ν2 bending vibration of the PO43– group. The triply degenerated ν4 bending
vibrations appeared as the peaks at 565 and 602 cm–1. The band at 963 cm–1 corresponds to ν1,
whereas the ν3 vibrations of PO43– ions showed the bands at 1033 and 1098 cm–1. Figure 1A,b CS polymer N–H
and O–H stretching vibration peaks appeared at 1653 and 1635
cm–1, respectively. The spectrum of GO in Figure 1A,c clearly shows
oxygen-possessing groups at 1054, 1223, 1395, 1622, and 1729 cm–1. These correspond to the C–O stretching vibration,
C–OH stretching vibration, C–O–H deformation
vibration, C–C stretching vibration, and CO stretching vibration
of COOH groups.24 Meanwhile, the spectra
of the GO/HAP composite in Figure 1A,d confirmed the presence of graphene oxide sheets
by the emergence of clear absorption bands of methylene (CH2) groups nearly around 2854 and 2918 cm–1. The
stretching band of pure HAP peaks shifted from 1035 to 1029 cm–1 (Figure 1A,d) due to the interaction of HAP with GO. This indicates
the formation of strong hydrogen bonding between the HAP and GO sheets.25−28 In addition, the GO/HAP/CS composite, as revealed in Figure 1A,e–g, suggests that
there is no observable variation in the three compositions following
CS functionalization. However, a C=O absorption peak at 1654
cm–1 in CS shifted toward a lower region at 1621
cm–1 in the n-HA/CS/GO composite,
which was due to the synergistic effects of hydrogen bonding between
the CS and GO/HAP; also, the peak of −NH2 (1598
cm–1) did not appear, which may be due to the development
of −NH3+. The peak of asymmetry stretching
of −COO– was present at ∼1420 cm–1. These annotations stress upon the fact that there
is a presence of electrostatic interaction between −COO– of GO and −NH3+ of CS,
which resulted in the creation of GO/HAP/CS-1, GO/HAP/CS-2, and GO/HAP/CS-3
networks with the inclusion of HAP compound in Figure 1A,e–g. The FTIR spectrum of the CDDP
composite exhibits only a peak in array of the corresponding CDDP
characteristic peaks at 799, 1305, 1540, and 1651 cm–1 being visible in CDDP loaded in the GO/HAP/CS-3 composite was confirmed.
The broadness of the peak is 3200–3300 cm–1 due to the intermolecular hydrogen bonding between the CDDP and
GO/HAP/CS-3 composite. This is due to the electrostatic interaction
between CDDP and the polymer matrix. In the spectrum of CS, there
are two characteristic absorbance bands centered at 1653 and 1596
cm–1, which correspond to the C=O stretching
vibration of −NHCO– and the N–H bending of −NH2, respectively. Compared with those of pure CS and GO, both
peaks at 1596 cm–1 related to −NH2 absorbance vibration and at 1730 cm–1 belonging
to the C=O stretch of the carboxylic group disappear in the
spectra of CS/GO nanocomposites. Moreover, the band corresponding
to the C=O characteristic stretching of the amide group shifts
to a lower wavenumber, which could be ascribed to the synergistic
effect of hydrogen bonding between CS and the oxygenated groups in
GO and electrostatic interaction between polycationic CS and the negative
charge on the surface of GO in the GO/HAP/CS composite. The transmittance
percentage decreased with an increasing in the wt % of CS, as shown
in Figure 1B,e–g.

Figure 1 FTIR spectra
of (A) (a) HAP, (b) CS, (c) GO, (d) GO/HAP, (e) GO/HAP/CS-1,
(f) GO/HAP/CS-2, (g) GO/HAP/CS-3, and (h) GO/HAP/CS-3/CDDP composites.
(B, C) Zoomed FTIR region with wavenumbers 1200–1800 and 3200–3800
cm–1.

2.2 X-ray Diffraction (XRD)
The main
peaks of HAP were formed at 26, 31.6, 32.92, 35.7, 40, 46.74, and
54.10°, which could be indexed to the (002), (211), (112), (300),
(202), (222), and (213) lattice planes of the hexagonal HAP, respectively,
as shown in Figure 2A,a. This demonstrates that diffraction is stronger than the standard
diffraction pattern (JCPDS card no. 09-0432). The broad diffraction
peaks at 2θ = 9.5 and 19.5° indicate the XRD spectrum of
CS, as shown in Figure 2A,b. GO flakes showed a diffraction peak at 10.9° (Figure 2A,c). The XRD pattern
of GO/HAP shows characteristic diffraction peaks at 2θ = 25.7,
28.79, 32.34, and 39.9° constant with the XRD pattern of pure
HAP shown in Figure 2A,d. Typical peaks of CS around 2θ values of 11.3, 18.2, and
23° can be clearly seen from Figure 2A,e–g. The two primary peaks of CS
and GO resembled the hydrated crystalline arrangement. The broadened
peak at around 23° indicates the extension of the amorphous nature.30,31 In our case, together the hydrogen bonding and electrostatic interaction
may have contributed toward a reasonably ordered array of CS chains
along the rigid template offered by GO, Figure 2B,e–g.29 The two characteristic peaks of CDDP were observed at 2θ about
15 and 20°, as shown in Figure 2B,h. After incorporation of the CS matrix into GO/HAP,
the XRD pattern of the GO/HAP/CS nanocomposite shows only the CS diffraction
peaks, and the peak of GO disappears from the diffraction pattern
of GO/HAP/CS (Figure 2A), which clearly demonstrates the formation of GO sheets in the
composite CS polymer matrix and the disappearance of the regular and
periodic structure of graphene oxide.30 It is noticed that incorporation of CS less than 30 wt % to GO/HAP
slightly increases the intensity of the characteristic peaks of CS.
However, the intensity of the characteristic peaks of CS obviously
increases in the GO/HAP/CS composites, and characteristic peaks of
CS at around (2θ) 8.4, 11.3, 18.2, and 23° can be clearly
seen from Figure 2B.
The first two peaks correspond to the hydrated crystalline structure,
whereas the broadened peak at about 23° indicates the existence
of an amorphous structure.

Figure 2 (A) XRD spectra of (a) HAP, (b) CS, (c) GO,
(d) GO/HAP, (e) GO/HAP/CS-1,
(f) GO/HAP/CS-2, (g) GO/HAP/CS-3, and (h) GO/HAP/CS-3/CDDP composites.
(B) Zoomed spectra of composites between 20 and 40°.

2.3 Scanning Electron Microscopy
(SEM) and Transmission
Electron Microscopy (TEM) Morphological Analyses
The surface
morphologies of the GO/HAP, GO/HAP/CS, and CDDP-loaded GO/HAP/CS composites
were investigated through SEM and TEM technologies and are presented
in Figure 3. The images
in Figure 3a,b indicate
that HAP and GO had spherical and sheetlike morphologies, respectively. Figure 3c represents GO/HAP
composites, and it shows the spherical particles of HAP on the GO
surface. Figure 3d–i
shows the morphology of the CS-functionalized GO/HAP composites after
hydrothermal treatment with the increasing weight percent of CS. After
the hydrothermal treatment, HAP from the GO/HAP/CS composite has grown,
and the HAP fabricated by the hydrothermal method shows a typical
flowerlike porous morphology. HAP spheres are composed of thin flakes
with high aspect ratios of CS forming the flowerlike morphology (Figure 3d–i), which
suggests significant difference in the synthesis of the composite
biomaterial. The SEM image of the composite indicates unvarying porous
morphology. The HAP spheres are composed of thin flakes with high
aspect ratios of CS forming the flowerlike morphology, which suggests
significant difference in the synthesis of the composite biomaterial.
The c-axis-oriented hydroxyapatite surfaces are likely
to promote preferentially oriented growth through a cyclic process
of dissolution and re-precipitation, followed by homoepitaxial growth.
The remarkable morphological and microstructural changes after dissolution
suggest the capability of highly textured hydroxyapatite to act as
a tissue engineering scaffold with an interconnecting porous network
that may be beneficial for cellular activity. Figure 3j indicates the CDDP-loaded GO/HAP/CS-3 composites. Figure 3k,m represents the
TEM images of the GO/HAP/CS-3 and CDDP-loaded GO/HAP/CS-3 composites.
The TEM image of the GO/HAP/CS-3 flakes of flower structures is well
correlated with the SEM images of GO/HAP/CS-3 and GO/HAP/CS-3/CDDP.
The CDDP-loaded GO/HAP/CS-3 composite SADE spectrum is shown in the
inset image of Figure 3l,n. It shows the amorphous nature of the overall composite.

Figure 3 SEM images
of (a) HAP, (b) GO, (c) GO/HAP, (d, g) GO/HAP/CS-1,
(e, h) GO/HAP/CS-2, (f, i) GO/HAP/CS-3 and (j) GO/HAP/CS-3/CDDP composites.
TEM images of (k) GO/HAP/CS-3 and (m) GO/HAP/CS-3/CDDP; SADE images
of (l) GO/HAP/CS-3 and (n) GO/HAP/CS-3/CDDP.

2.4 Energy Dispersive X-ray Analysis (EDAX) Mapping
Moreover, an elemental analysis mapping was carried out to recognize
the distribution of elements in the composite material. Figure 4a,b reveals the SEM image and
EDAX spectrum of the GO/HAP/CS-3/CDDP composite. From the EDAX mapping
analysis, elemental distribution of the GO/HAP/CS-3/CDDP composite
is presented in Figure 4c. Calcium, phosphorus, oxygen, carbon, and nitrogen were found and
are shown in Figure 4d–h in different colors. This confirms that a part of the
GO/HAP/CS-3/CDDP composite clearly shows the distribution of C, Ca,
O, N, and P elements in the composite. It is thus clear that the GO/HAP/CS-3/CDDP
composite has an immense prospective to be used in the progress of
new bone formation and bone repair applications due to the presence
of HAP, GO, CS, and CDDP.

Figure 4 (a) SEM images of GO/HAP/CS-3/CDDP; (b) EDAX
spectrum of GO/HAP/CS-3/CDDP;
(c) elemental mapping of GO/HAP/CS-3/CDDP; and (d–h) elements
present in GO/HAP/CS-3/CDDP: Ca, P, O, C, and N.

2.5 Barrett–Joyner–Halenda (BJH)
and Brunauer–Emmett–Teller (BET) Analyses
The
pore volume, surface area, and pore diameter of the GO/HAP/CS-1, GO/HAP/CS-2,
and GO/HAP/CS-3 composites were investigated through BET analysis,
and BJH investigation revealed the mesoporous nature of the composite;
the results are presented in Table 1. A distinctive adsorption/desorption graph of the
mesosphere is shown in Figure 5.

Figure 5 BET analysis: (A, C, E) adsorption of GO/HAP/CS-1, GO/HAP/CS-2,
and GO/HAP/CS-3 and (B, D, F) desorption of GO/HAP/CS-1, GO/HAP/CS-2,
and GO/HAP/CS-3.

Table 1 Average
Structural Parameters and
Surface Properties of GO/HAP/CS-3 Nanocomposites
composite
ID	surface area (m2/g)	pore volume (cm3/g)	pore diameter
(nm)	
GO/HAP/CS-1	3.8	0.01854	4.489	
GO/HAP/CS-2	5.552	0.01926	5.92	
GO/HAP/CS-3	5.7887	0.0970	7.1798	
2.6 CDDP Loading Capacity (LC) and In Vitro CDDP
Release Analysis
The aim of this study is self-curing of
bone cancer through anticancer-drug-loaded composites. Thus, the investigation
of the CDDP loading capacity and CDDP releasing properties of the
GO/HAP/CS composite materials is very important in this regard. Figure 6a–c indicates
UV–visible spectra of the CDDP loading capacity of GO/HAP/CS-1,
GO/HAP/CS-2, and GO/HAP/CS-3 after 3 h. Initially, the CDDP absorption
peak appearing at the intensity range is nearly zero, and then, for
the composites vortexed for 3 h, the intensity increased to almost
0.89, 1.0, and 1.5, respectively. The loading capacities of GO/HAP/CS-1,
GO/HAP/CS-2, and GO/HAP/CS-3 were around 44.7, 50.44, and 78% respectively.
The in vitro UV–visible spectra of CDDP from GO/HAP/CS-3/CDDP
were performed in phosphate buffer saline (PBS) medium at pH 7.4,
and the corresponding discharge report is depicted in Figure 6d–f. The CDDP release
was 84.84, 74.44, and 67.34% over a period of 10 days for the composites
GO/HAP/CS-1/CDDP, GO/HAP/CS-2/CDDP, and GO/HAP/CS-3/CDDP. From the
releasing profile, it could be understood that GO/HAP/CS-3/CDDP demonstrated
the required quantity of drug release, which was observed with a constant
releasing rate. This could be partially due to the flake pore geometry
of the flowerlike morphology of the composite and the length of drug
releases from the GO/HAP/CS-3/CDDP composites. The constant release
rate further affirms that the composite can be a potential candidate
for curing of cancer diseases as well as proved to be helpful in new
bone formation.31Figure 6g represents the cumulative release of CDDP
from the GO/HAP/CS-3/CDDP composites.

Figure 6 UV–vis spectra of Loading Capacity
of (a) GO/HAP/CS-1, (b)
GO/HAP/CS-2; (c) GO/HAP/CS-3 and CDDP released from (d) GO/HAP/CS-1/CDDP,
(e) GO/HAP/CS-2/CDDP, and (f) GO/HAP/CS-3/CDDP; and (g) cumulative
release profile of CDDP released from GO/HAP/CS/CDDP composites.

2.7 Cell
Viability and Cytotoxicity
Figure S3 shows the MG63 osteoblast-like cells
cultured with different concentrations (0.2, 0.4, 0.6, 0.8, and 1.0
μg/mL) of GO/HAP/CS-3 and GO/HAP/CS-3/CDDP for 24 h. The viability
of MG63 osteoblast-like cells increased with the increasing sample
concentration from 0.2 to 1.0 μg/mL. Figure 7 shows augmentation of MG63 osteoblast-like
cells cultivated on the GO/HAP/CS-3 and GO/HAP/CS-3/CDDP composites.
The 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) assay shows that the number of MG63 osteoblast-like cells can
noticeably increase on HAP, GO/HAP, GO/HAP/CS-1, GO/HAP/CS, GO/HAP/CS-3,
and GO/HAP/CS-3/CDDP in comparison to that in pure HAP as control.
The culture time is extended from 1 to 7 and 14 days. The outcome
shows that MG63 cells can proliferate well on the prepared composite.
The viability activities of MG63 osteoblast-like cells cultivated
on the as-prepared composite are observed by optical microscopy. As
the main inorganic phase of the natural bone tissue, hydroxyapatite
(HA) nanoparticles are chosen as ingredients of bone scaffolds, which
have the potential to augment bone regeneration capability. Graphene
oxide improves the biological properties of scaffold materials and
promotes the osteoblast proliferation. Furthermore, the incorporation
of GO into HAP (GO/HAP) was nontoxic to osteoblasts and augments propagation
and osteogenic discrimination. In addition, one of the most promising
polymeric materials seems to be chitosan, a biopolymer.32 An increase in the concentration of CS (10,
20, 30 wt %) in the GO/HAP composite results in the biocompatibility,
osteoconductivity, and a lowest inflammatory response in MG63 osteoblast-like
cells on day 1, 7, and 14. The composite exhibits an admirable cell
viability performance because the MG63 osteoblast-like cells appear,
which can be observed from optical microscopic images. When the culturing
time of the MG63 cells is increased from 7 to 14 days, the culture
is more obvious on the CDDP-loaded GO/HAP/CS-3 composite. The GO/HAP/CS-3/CDDP
composite shows a major difference on day 14 compared with the GO/HAP/CS-3
composite, which is reported to encourage cell propagation and cell
expansion.

Figure 7 (A) Cell viability on HAP, GO/HAP, GO/HAP/CS-1, GO/HAP/CS-2, GO/HAP/CS-3,
and GO/HAP/CS-3/CDDP analyzed by optical microscopy on 1, 7, and 14
days. (B) Quantification of cell viability of MG63 osteoblast-like
cells measured by the MTT assay (n = 3, p < 0.005).

Figure 8A shows
the optical microscopy observation on A549 cells. The cytotoxicity
analyses of HAP, GO/HAP/CS-3, and GO/HAP/CS-3/CDDP are revealed in Figure 8A,B. The considerable
variations in the nature of toxicity of the GO/HAP/CS-3/CDDP composite
appeared in A549 cells with an increase in the number of days of incubation,
and it was attributed to the presence of CDDP in the composite (Figure 8A). Without CDDP
loading, GO/HAP/CS-3 shows slightly toxic nature due to the presence
of chitosan molecules in the composites.32 This consequence established that the GO/HAP/CS-3/CDDP composites
abridged the growth of cancer cells (Figure 8B). The MTT assay showed that the cell viability
exceeded 23% and the incubation of A549 cells with GO/HAP/CS-3/CDDP
composites concealed cell augmentation after 21 days, as shown in Figure 8B. Hence, the GO/HAP/CS-3/CDDP
composite diminishes osteosarcoma progression because one of the effectual
anti-bone-cancer agents is cisplatin.33 HAP as a prospective material for CDDP confirmed unremitting discharge
of the drug from HAP blocks.34 Chitosan
has power over anticancer doings by itself and an eminent study is
that chitosan diminishes the viability of osteosarcoma cells, except
not the normal cells from which osteosarcoma cells begin osteoblasts.35 Chitosan was also able to condense the viability
property on a prime bone cancer such as osteosarcoma. Thus, a chitosan
can be of considerable use for bone cancer patients.

Figure 8 (A) Cytotoxicity on HAP,
GO/HAP/CS-3, and GO/HAP/CS-3/CDDP investigated
by optical microscopy on 1, 7, 14, and 21 days. (B) Quantification
of cell viability of A549 cells measured by the MTT assay (n = 3, p < 0.005).

2.8 Cell Adhesion
For the investigation
of effects of composites on sustaining cell growth, we seeded MG63
osteoblast-like cells on pure HAP, GO/HAP, GO/HAP/CS-1, GO/HAP/CS-2,
GO/HAP/CS-3, and GO/HAP/CS-3/CDDP, which were examined by SEM for
morphology after 1 day, 7 days, and 14 days. The SEM micrograph indicates
that MG63 cells were spread over the composites. The ability of graphene
oxide to improve the biological properties of composite materials
and its ability to promote the adhesion of osteoblasts have been noticed
in this study. After 7 days of culturing, there were plenty of MG63
osteoblast-like cells observed on the GO/HAP/CS-3/CDDP composite. Figure 9 indicates the micrographs
of the adhesion on HAP, GO/HAP, GO/HAP/CS-1, GO/HAP/CS-2, GO/HAP/CS-3,
and GO/HAP/CS-3/CDDP composites. Chitosan, a biopolymer, acts as a
provider of better environment for MG63 osteoblasts cells. The GO/HAP/CS-3/CDDP
composite has a suitable structure to mimic a temporary extracellular
matrix (ECM), which can control cellular behaviors, promote MG63 cell
adhesion, and provide appropriate microenvironments for MG63 osteoblast
cells.36,37 The GO/HAP/CS-3/CDDP composite revealed
an admirable cell adhesion performance because MG63 osteoblast-like
cells show cytoplasmic extension and filopodia can be observed on
the MG63 osteoblast-like cells.

Figure 9 Morphology of cell adhesion of osteoblast-like
cells (MG63) cultured
in the presence of HAP, GO/HAP, GO/HAP/CS-1, GO/HAP/CS-2GO/HAP/CS-3,
and GO/HAP/CS-3/CDDP on 1, 7, and 14 days.

2.9 Alkaline Phosphatase (ALP) Activity
ALP is a significant osteogenic discrimination and biochemical pointer
of osteoblasts. The GO/HAP/CS-3 and GO/HAP/CS-3/CDDP composites promote
ALP production from osteoblast-like cells (Figure 10), which increases with the increasing culture
time. For the GO/HAP/CS-3 composites alone, ALP concentration increased
from 2.6 mM on day 1 to almost 4.9 mM on day 14. Indeed, with the
GO/HAP/CS-3/CDDP composites, ALP activity was 4.2 mM at day 1 and
7.1 mM at day 14 (p < 0.005). The presence of
CDDP in the GO/HAP/CS-3/CDDP composites significantly promoted the
ALP activity as compared to that of GO/HAP/CS-3 alone.38 These data show that the ALP activity on osteoblast-like
cells increases when CDDP is supplemented with GO/HAP/CS-3.

Figure 10 ALP activity
on GO/HAP/CS-3 and GO/HAP/CS-3/CDDP on 1, 7, and 14
days (n = 3, p < 0.005).

2.10 Gene
Expression
The analysis of
gene expression on MG63 osteoblast-like cells using the osteogenic
initiation culture was analyzed by quantitative reverse transcription-polymerase
chain reaction (qRT-PCR) investigation, Figure 11a–c. The gene articulation like Runx2,
ALP, and OCN on GO/HAP/CS-3 and GO/HAP/CS-3/CDDP was investigated.
The mRNA transcript levels of ALP in GO/HAP/CS-3 and GO/HAP/CS-3/CDDP
composites expanded fundamentally in contrast to those in GO/HAP/CS-3/CDDP
congregation. A comparable prototype was seen in the osteogenic transformation
factor Runx2 through amplification and partly covering to that on
GO/HAP/CS-3 and GO/HAP/CS-3/CDDP. The OCN expression level of GO/HAP/CS-3
and GO/HAP/CS-3/CDDP get together was mainly up-managed with augment
and superimpose than GO/HAP/CS-3 and GO/HAP/CS-3/CDDP congregation.
It is well known that CDDP fulfills a major purpose in bone mineral
homeostasis and that it might in addition perform as a bioactive protein
that helps in augmentation of osteogenisis.39,40

Figure 11 Gene expression of (a) ALP, (b) Runx2, and (c) osteocalcin in MG63
osteoblast-like cells cultivated on GO/HAP/CS-3 and GO/HAP/CS-3/CDDP
for days 1, 7, and 14 (n = 3, p <
0.005).

3 Conclusions
Hydrothermal-assisted synthesis of GO/HAP/CS-3 was used to achieve
a flowerlike morphology of HAP, GO, and CS, which exhibits a facile
technique for scheming the morphological characteristics of composites.
CDDP acts as a major chemotherapeutic remedy for the action of cancers.
The CDDP-loaded composite GO/HAP/CS-3 exhibits an excellent cell viability
behavior on MG63 osteoblast-like cells. The augmentation in cell viability
of cells of MG63 osteoblasts enhances pertaining to the increase in
the porosity, which serves a significant role in the medical trials.
The GO/HAP/CS-3/CDDP composite exhibits a cytoplasmic extension, and
filopodia can be observed on the MG63 osteoblast-like cells. The GO/HAP/CS-3/CDDP
composite should allow artificially favorable biomaterial in the tissue
engineering applications.

4 Materials and Methods
4.1 Materials
Ammonia solution (NH4OH), calcium
chloride dihydrate (CaCl2·2H2O), chitosan
(molecular weight, 50–190 kDa), cisplatin
(CDDP), diammonium hydrogen phosphate ((NH4)2HPO4), ethyl alcohol (C2H5OH), graphite,
hydrogen peroxide (H2O2), potassium permanganate
(KMnO4), phosphate buffer saline (PBS), phosphoric acid
(H3PO4), and sulfuric acid (H2SO4) were brought from Sigma-Aldrich, Mumbai, India. Analytical-grade
chemicals were used in all of the experiments with no any additional
cleansing. Deionized water was used in all of the experiments.

4.2 Preparation of GO
GO was synthesized
using powder graphite following the modified Hummer’s method.35 The experimental procedures were slightly modified
as follows: before preparation of GO, the graphite flakes were subjected
to ultrasonication for the formation of graphene sheets. Then, KMnO4 (18.0 g, 6 wt equiv) was supplemented slowly to a 9:1 mixture
of rigorous H2SO4/H3PO4 (360:40 mL) in six equal portions, producing a slight exothermic
reaction that should not exceed the temperature 35–40 °C,
and a graphene sheet (3.0 g, 1 equiv wt %) was formed. This reaction
was passionate to 50 °C with continuous stirring for 12 h. The
reaction temperature was reduced to room temperature (27 °C),
and the reaction mixture was discharged onto ice (400 mL) containing
30% H2O2 (3 mL).

4.3 Preparation
of GO/HAP Composite
Distinctively,
3 mg of GO was dispersed in 5 mL of DD water with continuous stirring
for 30 min. Then, 0.5 mM CaCl2·2H2O was
added into each of the 5 mL GO suspension under stirring for fine
mixing of each solution. Then, the 0.3 mM (NH4)2HPO4 aqueous solution was added slowly to the above mixture
and stirred vigorously on a magnetic stirrer. The pH of the reaction
mixture was maintained at pH 10.0 with the help of ammonia solution.
Stirring was continued for about 30 min. The whole solution was ultrasonicated
for 30 min, and the solution was slowly filtered using a vacuum-assisted
Buchner funnel, followed by washing with 100 mL of water three times
to obtain the HAP/GO composite. Finally, the resulting precipitate
was dried at 50 °C. Throughout the synthesis, the oxygen-containing
functional groups on GO surfaces act as receptor sites for Ca2P through electrostatic interactions; these anchored cations
can in situ react with phosphate ions to obtain apatite nanoparticles.
The distribution and the microstructures of HAP on graphene are mainly
influenced by the amounts and types of oxygenated groups on the GO
and the concentration of calcium and phosphorus in the reagents. Composites
prepared in this method are expected to increase the interfacial bonding
between GO and HAP.

4.4 Preparation of GO/HAP/CS
Composites
The quantity of CS has considerably influenced
the potency of the
synthesizing hydrogels. Considering the solubility boundary of CS
in acetic acid solution, we used different weight percentages (10,
20, 30 wt %) of CS aqueous solutions to prepare the composites. Different
weight percentages of the CS polymer solution were added into the
GO/HAP composite, and then it was ultrasonicated for 30 min (5 s on,
3 s off), followed by pouring of the suspension into a sealed autoclave.
It was heated to 180 °C for 2 h in a muffle furnace and, afterward,
allowed to cool to room temperature (27 °C) to obtain a GO/HAP/CS-1,
GO/HAP/CS-2, and GO/HAP/CS-3 composites with 10, 20, and 30 wt % CS,
respectively. The schematic diagram of GO/HAP/CS-3/CDDP is shown in Figure S1.

4.5 Cisplatin
(CDDP) Encapsulation/Entrapment
on GO/HAP/CS-1, GO/HAP/CS-2, and GO/HAP/CS-3 Composites
CDDP
(5 mg) was dissolved in acetone (1 mg/1 mL in acetone, 5 mL) along
with the addition of GO/HAP/CS-1, GO/HAP/CS-2, and GO/HAP/CS-3 with
the help of stirring using a magnetic stirrer at 1000 rpm. The resultant
mixture was centrifuged at 4000 rpm. Finally, the acquired GO/HAP/CS-1/CDDP,
GO/HAP/CS-2/CDDP, GO/HAP/CS-3/CDDP powder was lyophilized using a
lyophilizer (SSIPL-LYF/065/071216).

4.6 Physicochemical
Characterizations
4.6.1 Fourier Transform Infrared
(FTIR) Spectroscopy
The HAP, GO/HAP, GO/HAP/CS composites
and the CDDP-loaded GO/HAP/CS
composites were tested by a Bruker Tensor 27 Series FTIR spectrometer,
and 16 scans per sample were taken in the region of 400–4000
cm–1 with 2 cm–1 resolution. The
pellets were made for the FTIR test by crushing 0.2 g of the sample
powder together with 1 g of KBr and then pressing them into a transparent
disc.

4.6.2 X-ray Diffraction
The X-ray diffraction
(XRD) characterization was done to analyze the phase composition and
to precisely obtain the crystallinity of prepared HAP, GO/HAP, GO/HAP/CS
composites, and CDDP-loaded GO/HAP/CS composites. This test was accomplished
in a Bruker D8 Advance diffractometer with a monochromatic Cu Kα
source operated at 40 kV and 30 mA. An acceleration voltage of 30
kV and a current of 15 mA were applied. The operating range of this
test was over the 2θ range of 10–60° in step scan
mode with a step size of 0.02° and a scan rate of 0.02°/min.

4.6.3 Scanning Electron Microscopy (SEM)
The
morphology, EDAX and elemental mapping, and morphologies of the
GO/HAP, GO/HAP/CS, and CDDP-loaded GO/HAP/CS composites were examined
by SEM (VEGA3 TESCAN) by operating it at a voltage of 10 kV.

4.6.4 Transmission Electron Microscopy
The surface analyses
of the synthesized GO/HAP and GO/HAP/CS composites
and CDDP-loaded GO/HAP/CS composites were determined by high-resolution
transmission electron microscopy (HR-TEM, TECNAI F30). For sample
preparation for HR-TEM analysis, the synthesized nanoparticles and
their composites were dispersed in ethanol by ultrasonication up to
15 min. Afterward, these were loaded on a carbon-coated copper mesh.

4.6.5 Barrett–Joyner–Halenda (BJH)
and Brunauer–Emmett–Teller (BET) Analyses
Nitrogen
adsorption/desorption isotherms of GO/HAP/CS-1, GO/HAP/CS-2, and GO/HAP/CS-3
were assessed with a Tel Micro Tract analyzer (Bel cork, Japan) under
a nonstop adsorption condition at a constant temperature (77 K). At
the beginning of the analysis, GO/HAP/CS-1, GO/HAP/CS-2, and GO/HAP/CS-3
were degassed at 100 °C. BJH and BET analyses were used to find
out the surface area, pore volume, and pore diameter.41

4.6.6 Loading Capacity (LC)
on GO/HAP/CS-3
UV–visible spectroscopy was used to
study the loading capacity
of the composites formed. GO/HAP/CS-1/CDDP, GO/HAP/CS-2/CDDP, and
GO/HAP/CS-3/CDDP composites (10 mg of each) were washed using 2 mL
of acetone. Later, the solution was centrifuged. Afterward, complimentary
CDDP having acetone was freeze-dried. Finally, hexane was used to
extract the CDDP and a UV–vis spectrophotometer at 265 nm31 was used to measure the amount of CDDP loaded
into GO/HAP/CS-3.  

4.6.7 In Vitro Release Studies
The in
vitro discharge behavior of CDDP from CDDP-loaded GO/HAP/CS-1, GO/HAP/CS-2,
GO/HAP/CS-3 composites was studied via a dialysis membrane technique
using a PBS solution working at pH 7.4. Sample preparation included
sealing of 50 mg of GO/HAP/CS-1/CDDP, GO/HAP/CS-2/CDDP, and GO/HAP/CS-3/CDDP
composites into separate dialysis bags with the MWCO 12 000
Da. Then, 10 mL of the PBS solution containing CDDP-loaded composites
was stirred at 100 rpm and at 37 °C. The supernatant solution
was collected at different day interval by measured the concentration
of CDDP solution λmax value of 265 nm in a UV-spectroscopy
and replenishing among an identical quantity of new PBS medium.41,42

The following formula was used to calculate the % of drug
release  where AR is the absorbance of CDDP discharged
from the composite and AC is the total amount of CDDP loaded in the
composite.

4.6.8 Biodegradability
The biodegradability
of composites was analyzed for a time period of 28 days by putting
them in PBS at pH 7.4 and ambient temperature 27 °C, while keeping
the liquid-to-solid ratio at 0.5 mg/mL through stirring at 100 rpm.
The buffer solution was freshly prepared every 3rd day at 1st, 7th,
14th, 21th, and 28th day; the days were the specimens were taken from
them. The solution was then oven-dried at 60 °C for 24 h till
the stable weight was achieved. The degradation proportion was calculated
using the following formula  where W0 is the
early weight of the composite and Wt is
the weight at later time t after treatment

4.6.9 Cell Viability on Osteoblast-like Cell (MG63)
The National
Centre for Cell Science (NCCS), Pune, India, was chosen
for the procurement of the osteoblast-like cells MG63. The cells were
maintained in a strict stringent condition in Dulbecco’s modified
Eagle’s medium (DMEM) in a CO2 incubator at 37 °C
(with a humidifier) along with low glucose concentration (1 g/L),
fetal bovine serum (FBS-10%), and penicillin/streptomycin (1%). The
trypsin/EDTA solution was used after every 3 days to harvest the cells.
The effect of HAP, GO/HAP, GO/HAP/CS-1, GO/HAP/CS-2, GO/HAP/CS-3,
and GO/HAP/CS-3/CDDP nanocomposites on MG63 was recorded with the
help of the corresponding 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) assay. A 24-well plate was used to seed
the MG63 osteoblast-like cells at a density of 4 × 104 cells/well and co-cultivated with GO/HAP/CS-3 and GO/HAP/CS-3/CDDP
composites with a concentration of 1 μg/mL. The MTT assay was
used to assess the viability of MG63 osteoblast-like cells. After
an incubation of 1, 7, and 14 days, the sample solutions were taken
and the MTT solution (100 μL, 5 mg/mL) was added in 1 mL culture
medium to each well plate and then again incubated for 4 h at 37 °C.
Afterward, 1 mL of dimethyl sulfoxide was supplemented to it and the
supernatant medium was collected separately, followed by centrifugation.
The wavelength of 570 nm was used to record the ocular density of
the superincumbent solution.43

4.6.10 Cytotoxicity
Cell differentiation
was studied on human lung cancer (A549) cells, and they were purchased
from the National Center for Cell Science (NCCS), Pune, India. A549
cells were seeded in 24-well plates containing Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% FBS and penicillin
(100 U/mL)/streptomycin (100 U/mL) (Gibco, Grand Island, CA) and cultivated
for 24 h. The cells were incubated at 37 °C (RT) in CO2 and were observed thorough MTT assay techniques. The composite was
tested on cells incubated for different days, 1, 7, and 14. The OD
values were recorded at a λmax value of 490 nm. The
composite morphology was investigated by optical microscopy, and the
following formula was used to calculate the cytotoxicity of the composite  

4.6.11 MG63 Osteoblast-like Cell Adhesion on Composites
Cell adhesion analysis was recorded using the cell viability protocol.
Subsequent to day 1, day 7, and day 14 of incubation, cell-film assemblies
were cleaned with PBS and fixed with 3% glutaraldehyde at 4 °C.
These samples were dried in air. Dried samples were mounted on aluminum
stubs with gold sputter-coating. The prepared samples were hence perspective
under SEM at an extent voltage of 10 kV29 the investigations were continual three times.

4.6.12 Alkaline Phosphatase (ALP) Activity
The expression
of alkaline phosphatase was assessed with the composites
on 24-well plates at a density of 4 × 104 cells. For
each specimen of day 1, day 7, and day 14, the cells were thoroughly
washed with PBS solution and lysated in Triton X-100 (0.1 vol %) using
the typical freeze–defrost rotations. The calorimetric test
was used to determine the ALP activity in the lysate with an ALP reagent
consisting of a p-nitrophenyl phosphate substrate.40 A microplate reader quantifying at 405 nm was
used to obtain the absorbance of p-nitrophenol.

4.6.13 Gene Expression
Specific bone-related
genes of transcript mRNA from MG63 osteoblast-like cells cultivated
on the synthesized nanocomposite with a concentration of 10 μg/mL
were tested by real-time qRT-PCR analysis. Full RNA was isolated,
and indiscriminate hexamer-primed cDNA production was executed on
them. A RevertAid first strand cDNA union pack was used. In a 40-cycle
PCR using a Rotor-gene Q analyzer, the cDNA was used as a template
base. To determine the real-time PCR, the Maxima SYBR green/ROX qPCR
master mix was used. It was further followed by softening bend investigation
to verify PCR specificity.39,40 In Rotor-Gene Q software
(Corbett), limit cycle normal was used for calculation and all of
the experiments were repeated twice. ΔCt analysis was used to calculate the relative gene expression.
Each target gene’s comparative expression levels were normalized
besides the general housekeeping gene’s Ct value. The reverse and forward primers of the handpicked
genes are listed in Table 2.

Table 2 Primary Sequences Used for PCR Amplification
genes	forward primer
sequence (5′–3′)	reverse
primer
sequence (5′–3′)	gene
bank
no.	size	
ALP	CGGCCATCCTATATGGTAACGG	CAGGAGGCCATACGCCATCACA	NM_001287172	72	
Runx2	CCAACTTCCTGTGCTCCGTG	GTGAAACTCTTGCCTCGTCCG	NM_001146038	151	
osteocalcin	GACCCTCTCTCTGCTCACTCT	GACCTTACTGCCCTCCTGCTTG	NM_007541.3	112	
Supporting Information Available
The Supporting
Information
is available free of charge on the ACS Publications website at DOI: 10.1021/acsomega.8b02090.Schematic diagram,
biodegradability, and in vitro cell
viability (Figures S1–S3) (PDF)



Supplementary Material
ao8b02090_si_001.pdf

 M.R. acknowledges
major financial support from the Department of Science and Technology,
Science and Engineering Research Board (ref YSS/2015/001532; New Delhi,
India) and also acknowledges the DST-PURSE program for the purchase
of SEM and FTIR and UPE programs for the purchase of TEM.

The authors
declare no competing financial interest.
==== Refs
References
Rinaudo M. 
Chitin and
chitosan: Properties and applications . Prog.
Polym. Sci. 
2006 , 31 , 603 –632 . 10.1016/j.progpolymsci.2006.06.001 .
Ni J. H. ; Shi Y. L. ; Yan F. Y. ; Chen J. Z. ; Wang L. 
Preparation
of hydroxyapatite-containing titania coating on titanium substrate
by micro-arc oxidation . Mater. Res. Bull. 
2008 , 43 , 45 –53 . 10.1016/j.materresbull.2007.02.019 .
Yao Z. Q. ; Ivanisenko Y. ; Diemant T. ; Caron A. ; Chuvilin A. ; Jiang J. Z. ; et al. Synthesis and properties of hydroxyapatite-containing
porous titania coating on ultrafine-grained titanium by micro-arc
oxidation . Acta Biomater. 
2010 , 6 , 2816 –2825 . 10.1016/j.actbio.2009.12.053 .20056173 
Li M. ; Pan X. ; Feng Y. ; Sijie L. ; Changhong R. ; Zhichen Y. ; Ang L. ; Huafang L. ; Xunming J. ; Yufeng Z. ; Cheng Y. 
An overview of graphene-based hydroxyapatite
composites for orthopedic applications . Bioactive
Mater. 
2018 , 3 , 1 –18 . 10.1016/j.bioactmat.2018.01.001 .
Neelgund G. M. ; Oki A. ; Luo Z. 
In situ deposition
of hydroxyapatite on graphenenanosheets . Mater.
Res. Bull. 
2013 , 48 , 175 –179 . 10.1016/j.materresbull.2012.08.077 .25110359 
Liu Y. ; Huang J. ; Li H. 
Synthesis
of hydroxyapatite–reduced
graphite oxide nanocomposites for biomedical applications: oriented
nucleation and epitaxial growth of hydroxyapatite . J. Mater. Chem. B 
2013 , 1 , 1826 –1834 . 10.1039/c3tb00531c .
Baradaran S. ; Moghaddam E. ; Basirun W. ; Mehrali M. ; Sookhakian M. ; Hamdi M. ; Moghaddam M. ; Alias Y. 
Mechanical properties
and biomedical applications of a nanotube hydroxyapatite-reduced graphene
oxide composite . Carbon 
2014 , 69 , 32 –45 . 10.1016/j.carbon.2013.11.054 .
Kalbacova M. ; Broz A. ; Kong J. ; Kalbac M. 
Graphene substrates
promote adherence of human osteoblasts and mesenchymal stromal cells . Carbon 
2010 , 48 , 4323 –4329 . 10.1016/j.carbon.2010.07.045 .
Dubey N. ; Bentini R. ; Islam I. ; Cao T. ; Neto A. H. C. ; Rosa V. 
Graphene: A Versatile Carbon-Based
Material for Bone
Tissue Engineering . Stem Cells Int. 
2015 , 2015 , 1 –12 . 10.1155/2015/804213 .
Hu W. ; Peng C. ; Luo W. ; Lv M. ; Li X. ; Li D. ; Huang Q. ; Fan C. 
Graphene-based antibacterial paper . ACS Nano 
2010 , 4 , 4317 –4323 . 10.1021/nn101097v .20593851 
Janković A. ; Erakovic S. ; Vukasinovic-Sekulic M. ; Miskovic-Stankovic V. ; Park S. J. ; Rhee K. Y. 
Graphene-based antibacterial
composite
coatings electrodeposited on titanium for biomedical applications . Prog. Org. Coat. 
2015 , 83 , 1 –10 . 10.1016/j.porgcoat.2015.01.019 .
Kim I. Y. ; Seo S. J. ; Moon H. S. ; et al. Chitosan and its derivatives
for tissue engineering applications . Biotechnol.
Adv. 
2008 , 26 , 1 –21 . 10.1016/j.biotechadv.2007.07.009 .17884325 
Kumar M. N. V. R. 
A
Review of Chitin and Chitosan Applications . React. Funct. Polym. 
2000 , 46 , 1 –27 . 10.1016/S1381-5148(00)00038-9 .
Chabba S. ; Matthews G. F. ; Netravali N. A. 
Green composites
using cross-linked
soy flour and flax yarns . Green. Chem. 
2005 , 7 , 576 –581 . 10.1039/b410817e .
Florczyk S. J. ; Liu G. ; Kievit F. M. ; Lewis A. M. ; Wu J. D. ; Zhang M. 
3D Porous
Chitosan-Alginate Scaffolds: A New Matrix for Studying Prostate Cancer
Cell-Lymphocyte Interactions In Vitro . Adv. Healthcare Mater. 
2012 , 1 , 590 –599 . 10.1002/adhm.201100054 .
Fang X. ; Sittadjody S. ; Gyabaah K. ; Opara E. C. ; Balaji K. C. 
Novel 3D
Co Culture Model for Epithelial-Stromal Cells Interaction in Prostate
Cancer . PLoS One 
2013 , 8 , e7518710.1371/journal.pone.0075187 .24073251 
Sharma C. ; Dinda A. K. ; Potdar P. D. ; Chou C. F. ; Mishra N. C. 
Fabrication
and characterization of novel nano-biocomposite scaffold of chitosan-gelatin-alginate-hydroxyapatite
for bone tissue engineering . Mater. Sci. Eng.,
C 
2016 , 64 , 416 –427 . 10.1016/j.msec.2016.03.060 .
Liu H. ; Xi P. ; Xie G. ; Shi Y. ; Hou F. ; Huang L. ; Chen F. ; Zeng Z. ; Shao C. ; Wang J. 
Simultaneous
reduction and surface functionalization of graphene oxide for hydroxyapatite
mineralization . J. Phys. Chem. C 
2012 , 116 , 3334 –3341 . 10.1021/jp2102226 .
Cisplatin and Platinum Analogs in Cancer and Chemotherapy: Principles
and Practice ; Reed E. , Kohn K. W. , Chabner B. A. , Collins  , Eds.; Lippincott
Co. : Philadelphia , 1990 ; pp 465 –490 .
Rey C. ; Kim H. M. ; Gerstenfeld L. ; Glimcher M. J. 
Structural chemical
characteristics and maturation of the calcium-phosphate crystals formed
during the calcification of the organic matrix synthesized by chicken
osteoblasts in cell culture . J. Bone Miner Res. 
1995 , 10 , 1577 –1588 . 10.1002/jbmr.5650101020 .8686515 
Abarrategi A. ; Tornin J. ; Martinez-Cruzado L. ; Hamilton A. ; Martinez-Campos E. ; Rodrigo J. P. ; Victoria
Gonzalez M. ; Baldini N. ; Garcia-Castro J. ; Rodriguez R. 
Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and
Targeted Therapies . Stem Cells Int. 
2016 , 2016 , 363176410.1155/2016/3631764 .27366153 
Rosenberg A. E. ; Cleton-Jansen A. M. ; De Pinieux G. ; Fletcher C. D. M. ; Bridge J. A. ; Hogendoorn P. C. W. ; Mertens F. 
Conventional osteosarcoma, in WHO
Classification of Tumors of Soft Tissue and Bone . Int. Agency Res. Cancer 
2013 , 4 , 282 –288 .
Botter S. M. ; Neri D. ; Fuchs B. 
Recent advances in Osteosarcoma . Curr. Opin. Pharmacol. 
2014 , 16 , 15 –23 . 10.1016/j.coph.2014.02.002 .24632219 
Fan Z. ; Wang J. ; Wang Z. ; Ran H. ; Li Y. ; Niu L. ; Gong P. ; Liu B. ; Yang S. 
One-pot synthesis of
graphene/hydroxyapatite nanorod composite for tissue engineering . Carbon 
2014 , 66 , 407 –416 . 10.1016/j.carbon.2013.09.016 .
Liu Y. ; Huang J. ; Li H. 
Synthesis
of hydroxyapatite–reduced
graphite oxide nanocomposites for biomedical applications: oriented
nucleation and epitaxial growth of hydroxyapatite . J. Mater. Chem. B 
2013 , 1 , 1826 –1836 . 10.1039/c3tb00531c .
Baradaran S. ; Moghaddam E. ; Basirun W. ; Mehrali M. ; Sookhakian M. ; Hamdi M. ; Moghaddam M. ; Alias Y. 
Mechanical properties
and biomedical applications of a nanotube hydroxyapatite-reduced graphene
oxide composite . Carbon 
2014 , 69 , 32 –45 . 10.1016/j.carbon.2013.11.054 .
Temmei I. ; Makoto S. ; Tetsushi T. 
Enhanced ALP activity
of MG63 cells
cultured on hydroxyapatite-poly(ethylene glycol) hydrogel composites
prepared using EDTA-OH . Biomed. Mater. 
2015 , 10 , 01502510.1088/1748-6041/10/1/015025 .25730608 
Brigaud I. ; Agniel R. ; Leroy-Dudal J. ; Kellouche S. ; Ponche A. ; Bouceba T. ; Mihailescu N. ; Sopronyi M. ; Viguier E. ; Ristoscu C. ; Sima F. ; Mihailescu I. N. ; Carreira A. C. O. ; Sogayar M. C. ; Gallet O. ; Anselme K. 
Synergistic effects of BMP-2, BMP-6 or BMP-7 with human
plasma fibronectin onto hydroxyapatite coatings: A comparative study . Acta Biomater. 
2017 , 55 , 481 –492 . 10.1016/j.actbio.2017.04.013 .28434979 
Yang X. ; Feng Tu Y. ; Li L. ; Shang S. ; Xiao-ming T. 
Well-Dispersed
Chitosan/Graphene Oxide Nanocomposites . ACS
Appl. Mater. Interfaces 
2010 , 2 , 1707 –1713 . 10.1021/am100222m .20527778 
Anitha A. ; Deepthy M. ; Sivanarayanan T. B. ; Manzoor K. ; Chandini
Mohan C. ; Shantikumar Nair V. ; Manitha Nair B. 
Bioinspired
Composite Matrix Containing Hydroxyapatite–Silica Core–Shell
Nanorods for Bone Tissue Engineering . ACS Appl.
Mater. Interfaces 
2017 , 9 , 26707 –26718 . 10.1021/acsami.7b07131 .28741921 
Murugan S. ; Rajan M. ; Alyahya S. A. ; Alharbi N. S. ; Shine K. ; Suresh Kumar S. 
Development
of self-repair nano-rod scaffold materials
for implantation of osteosarcoma affected bone tissue . New J. Chem. 
2018 , 42 , 725 –734 . 10.1039/C7NJ03143B .
O’Brien F. J. 
Biomaterials
& scaffolds for tissue engineering . Mater.
Today 
2011 , 14 , 88 –95 . 10.1016/s1369-7021(11)70058-x .
Tan M. L. ; Shao P. ; Friedhuber A. M. ; Van Moorst M. ; Elahy M. ; Indumathy S. ; Dunstan D. E. ; Wei Y. ; Dass C. R. 
The potential role
of free chitosan in bone trauma
and bone cancer management . Biomaterials 
2014 , 35 , 7828 –7838 . 10.1016/j.biomaterials.2014.05.087 .24947230 
Hasegawa M. ; Yagi K. ; Iwakawa S. ; Hirai M. 
Chitosan induces apoptosis
via caspase-3 activation in bladder tumor cells . Jpn. J. Cancer Res. 
2001 , 92 , 459 –466 . 10.1111/j.1349-7006.2001.tb01116.x .11346469 
Nam K. S. ; Shon Y. H. 
Suppression of metastasis
of human breast cancer cells
by chitosan oligosaccharides . J. Microbiol.
Biotechnol. 
2009 , 19 , 629 –633 . 10.4014/jmb.0811.603 .19597323 
Levengood S. K. L. ; Zhang M. 
Chitosan-based scaffolds for bone tissue engineering . J. Mater. Chem. B 
2014 , 2 , 3161 –3184 . 10.1039/c4tb00027g .24999429 
Almeida C.
R. ; et al. Impact
of 3-D printed PLA- and chitosan-based scaffolds on human
monocyte/macrophage responses: Unraveling the effect of 3-D structures
on inflammation . Acta Biomater. 
2014 , 10 , 613 –622 . 10.1016/j.actbio.2013.10.035 .24211731 
Yu P. ; Bao R.-Y. ; Shi X.-J. ; Yang W. ; Ming-Bo Y. 
Self-assembled
high-strength hydroxyapatite/graphene oxide/chitosan composite hydrogel
for bone tissue engineering . Carbohydr. Polym. 
2017 , 155 , 507 –515 . 10.1016/j.carbpol.2016.09.001 .27702542 
Jafari S. ; Maleki-Dizaji N. ; Barar J. ; Barzegar-Jalali M. ; Rameshrad M. ; Adibika K. 
Methyl prednisolone acetate-loaded
hydroxyapatite nanoparticles as a potential drug delivery system for
treatment of rheumatoid arthritis: In vitro and in
vivo evaluation . Eur. J. Pharm. Sci. 
2016 , 91 , 225 –235 . 10.1016/j.ejps.2016.05.014 .27189528 
Sumathra M. ; Munusamy M. A. ; Alarfaj A. A. ; Rajan M. 
Osteoblast response
to Vitamin D3 loaded cellulose enriched hydroxyapatite Mesoporous
silica nanoparticles composite . Biomed. Pharmacother. 
2018 , 103 , 858 –868 . 10.1016/j.biopha.2018.04.078 .29710502 
Balakrishanan M. H. ; Rajan M. 
Size-controlled synthesis
of biodegradable nanocarriers for targeted
and controlled cancer drug delivery using salting out cation . Bull. Mater. Sci. 
2016 , 39 , 69 –77 . 10.1007/s12034-015-0946-4 .
Firoozi N. ; Rezayan A. H. ; Jamal
Tabatabaei Rezaei S. ; Mir-Derikvand M. ; Reza Nabid M. ; Nourmohammadi J. ; Mohammadneja A. 
Synthesis
of poly(ε-caprolactone)-based polyurethane semi-interpenetrating
polymer networks as scaffolds for skin tissue regeneration . Int. J. Polym. Mater. Polym. Biomater. 
2017 , 66 , 805 –811 . 10.1080/00914037.2016.1276059 .
Nie W. ; Peng C. ; Zhou X. ; Chen L. ; Wang W. ; Zhang Y. ; Ma P. X. ; He C. 
Three-dimensional porous
scaffold by self-assembly of reduced graphene oxide and nano-hydroxyapatite
composites for bone tissue engineering . Carbon 
2017 , 116 , 325 –337 . 10.1016/j.carbon.2017.02.013 .

